The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Open accessAbstract
BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) occurs in approximately 3% of persons 50 years of age or older. METHODS: We studied 1384 patients who were residing in southeastern Minnesota and in whom MGUS was diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median follow-up was 34.1 years (range, 0.0 to 43.6). The primary end point was progression to multiple myeloma or another plasma-cell or lymphoid disorder. RESULTS: During 14,130 person-years of follow-up, MGUS progressed in 147 patients (11%), a rate that was 6.5 times (95% confidence interval [CI], 5.5 to 7.7) as high as the rate in the control population. The risk of progression without accounting for death due to competing causes was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Among patients with IgM MGUS, the presence of two adverse risk factors - namely, an abnormal serum free light-chain ratio (ratio of kappa to lambda free light chains) and a high serum monoclonal protein (M protein) level (≥1.5 g per deciliter) - was associated with a risk of progression at 20 years of 55%, as compared with 41% among patients who had one adverse risk factor and 19% among patients who had neither risk factor. Among patients with non-IgM MGUS, the risk of progression at 20 years was 30% among those who had the two risk factors, 20% among those who had one risk factor, and 7% among those who had neither risk factor. Patients with MGUS had shorter survival than was expected in the control population of Minnesota residents of matched age and sex (median, 8.1 vs. 12.4 years; P<0.001). CONCLUSIONS: Significant differences were noted in the risk of progression between patients with IgM MGUS and those with non-IgM MGUS. Overall survival was shorter among patients with MGUS than was expected in a matched control population. (Funded by the National Cancer Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This tumor does not develop rapidly; instead, it may take decades for symptoms and organ damage to manifest.4-8”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MM is well-described to be universally preceded by precursor states, often decades before it is even diagnosed.”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several epidemiological studies have shown that patients with MGUS and SMM might experience progression to MM over an extremely variable timeframe. Some patients progressed to MM within 2 years of diagnosis, while others may progress after 10 to 20 years or might never progress at all.4-6,75”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationAsymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Tutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M. F., & Geskus, R. B. (2006) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,458
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationHistory of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Self-citation
Research works printed but not linked: 1
- Kyle R Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR Conway de Macario E Folds JD Lane HC Nakamura RM eds. Manual of clinical laboratory immunology. 5th ed. Washington DC: ASM Press 1997:156-76.
Cited by
Sorted by citations
Items 401–500 of 646
Morgan, G. J., & Prokaeva, T. B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1622207 · Cited by 2
Advanced imaging in evaluation of bone disease of multiple myeloma
Huang, W., Dong, H., Ji, X., & Xia, S. (2020) · Chinese Journal of Academic Radiology · doi:10.1007/s42058-020-00038-y · Cited by 2
Case Report: Monoclonal Gammopathy of Undetermined Significance is Associated with Loa loa Infection
Laskar, D. B., Rose, M., Gupta, R., Tanowitz, H. B., & Haseeb, M. A. (2018) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.18-0351 · Cited by 2
Löscher, W. N., & Iglseder, B. (2020) · Der Internist · doi:10.1007/s00108-020-00748-6 · Cited by 2
Monoclonal gammopathies of undetermined significance and smoldering myeloma
Jurczyszyn, A. J., Hutch, R., Waszczuk‐Gajda, A., Suska, A., Krzanowska, K., & Vesole, D. H. (2020) · Acta Haematologica Polonica · doi:10.2478/ahp-2020-0035 · Cited by 2
Durot, É., & Delmer, A. J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17699 · Cited by 2
Novosad, O., Rudiuk, T., Shevchuk, L., Kundina, V., & Schmidt, A. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad004 · Cited by 2
Giannakoulas, A., Nikolaidis, M., Amoutzias, G. D., & Giannakoulas, N. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1390105 · Cited by 2
Lee, H., Tay, J., Street, L. E., Duggan, P. R., & Jimenez-Zepeda, V. H. (2021) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.21000078 · Cited by 2
Some Thoughts on Exposure to the World Trade Center Wreckage and Cancer
Brawley, O. W. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0498 · Cited by 2
Potential Diagnostic Value of Circulating miRNA for Multiple Myeloma: A Meta-Analysis.Preprint
Zhang, W., Gao, S., Wang, Y., & Zhang, G. (2020) · Research Square · doi:10.21203/rs.3.rs-47626/v1 · Cited by 2
Evaluation of Plasma Cell Neoplasms
Roshal, M., Gao, Q., Hutcherson, S. M., Thoren, K. L., Zhu, M., & Murata, K. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch109 · Cited by 1
Cao, Q., Qi, H., Li, Y., & Liu, Q. (2020) · Panminerva Medica · doi:10.23736/s0031-0808.19.03609-7 · Cited by 1
Evaluation of Retinal Blood Flow in Patients with Monoclonal Gammopathy Using OCT Angiography
Czakó, C. N., Gerencsér, D., Kormányos, K., Kéki‐Kovács, K., Németh, O., Tóth, G., Sándor, G. L., Csorba, A., Langenbucher, A., Nagy, Z. Z., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165227 · Cited by 1
Liu, Y., Fan, G., He, F., Tong, H., Jiang, C., Xu, P., & Wang, J. (2023) · Allergologia et Immunopathologia · doi:10.15586/aei.v51i5.795 · Cited by 1
Evaluation of Sarcopenia in Patients with Monoclonal Gammopathy of Undetermined Significance
Kul, A. N., & Tuna, M. K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123458 · Cited by 1
Ferla, V., Farina, F., Perini, T., Marcatti, M., & Ciceri, F. (2024) · Pharmaceuticals · doi:10.3390/ph17070901 · Cited by 1
Anti–Myelin-Associated Glycoprotein Neuropathy
Morganroth, J., & Karam, C. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200368 · Cited by 1
Screening for monoclonal gammopathies of undetermined significance: A prospective study
Maataoui, A. E., & Farhat, S. (2025) · Journal of Public Health in Africa · doi:10.4102/jphia.v16i1.714 · Cited by 1
del-Pozo-Lérida, S., Sabala, A., Widmer-Pintos, J. N., Arnaldos-López, C., Martínez, M., Salcedo, M. T., & Quer, A. (2025) · Cornea · doi:10.1097/ico.0000000000003880 · Cited by 1
Paraproteinemic polyneuropathies in patients with plasma cell neoplasms
Linkou, M. V., Козич, Ж. М., & Усова, Н. Н. (2025) · Medical and Biological Problems of Life Activity · doi:10.58708/2074-2088.2025-1(33)-29-37 · Cited by 1
Clinical Utility of Routine Monoclonal Gammopathy Testing in the Evaluation of Peripheral Neuropathy
Maberry, M. D., Smith, C. J., & Go, R. S. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09528-0 · Cited by 1
Emerging roles of protein arginine methyltransferase in multiple myeloma
Qaddoura, S. F., Liu, E., Walker, B. A., & Tran, N. T. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201003 · Cited by 1
A simple genomic score to predict progression of multiple myeloma
(2025) · Nature Genetics · doi:10.1038/s41588-025-02199-x · Cited by 1
Lecture 4. Clonal Plasma Cell Precursors
Dispenzieri, A. A. (2025) · Hematological Oncology · doi:10.1002/hon.70077 · Cited by 1
Self-citationMonoclonal Gammopathy of Unknown Significance (MGUS): A Mortality Analysis
Willwerth, G. (2025) · Journal of Insurance Medicine · doi:10.17849/insm-52-2-1-7.1 · Cited by 1
Eidbo, S., Malin, J. H., Barnett, M. J. L., Stavola, T., Ibe, F. O., Pereira, L. C., Shah, A., & Mayo, R. (2025) · Cureus · doi:10.7759/cureus.88087 · Cited by 1
Association and Prognostic Significance of Comorbidities in Individuals With MGUS
Bawek, S. J., Nassour, N., Alharbi, M., Hutson, A. D., Parker, S., Tario, J. D., Hassan, H., Abrams, S. I., McCarthy, P. L., Hillengass, J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.019 · Cited by 1
Oskam, N., Verhaar, W., Heer, P. O., Amaador, K., Derksen, N. I. L., Keijzer, S., Kersten, M. J., Streutker, M., Vos, J. M. I., & Rispens, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1670408 · Cited by 1
Kodra, J. D., Choudhury, A., Hanley, J., Sullivan, C. W., & LoGiudice, A. J. (2026) · Seminars in Arthroplasty JSES · doi:10.1016/j.sart.2026.151561 · Cited by 1
van Veen, R., Baars, A. E., van Doorn, I., Michael, M. R., Bus, S. R., Broers, M. C., van der Pol, W. L., van Doorn, P. A., Drenthen, J., Verhamme, C., et al. (2026) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70116 · Cited by 1
Dogliotti, I., Jiménez, C., Peri, V., Ferrante, M., Musto, D., Mercadante, S., Zaccaria, G. M., Ghislieri, M., Benevolo, G., Ocio, E. M., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018435 · Cited by 1
MGUS prevalence among active-duty military personnel
Kazandjian, D. G., DeStefano, C. B., Darmon, S., Dew, A., Hill, E., Thoren, K. L., & Landgren, O. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01511-0 · Cited by 1
Stino, A. M., & Becker, B. E. (2026) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001748 · Cited by 1
Cadenas ligeras libres en suero en el diagnóstico de Gammapatías Monoclonales
Sierra, M. M., Arbeláez, P. E. J., Diaz, L. M., & Gálvez, K. (2019) · Revista avances en salud · doi:10.21897/25394622.1861 · Cited by 1
A Man With Recurrent Fever, Episodic Rash, and Pain
Aslam, F., Wiedmeier, J. E., & DiCaudo, D. J. (2020) · Arthritis Care & Research · doi:10.1002/acr.24142 · Cited by 1
Heaney, J. L. J., Ackermann, F., Paunet-Bobo, M., Mehlal, S., Jolly, É., Hachem, J., Védrenne, A., & Vasse, M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.07.034 · Cited by 1
Myeloma and Related Conditions
Hussein, S., Chari, A., Salem, F. E., & Madduri, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-56738-1.00014-2 · Cited by 1
Patologías cutáneas asociadas a gammapatías monoclonales: ¿qué sabemos hasta ahora?
Meza‐Romero, R., Andino‐Navarrete, R., Rojas, P., Vargas, S., & Jerez, J. (2021) · Revista médica de Chile · doi:10.4067/s0034-98872021000500747 · Cited by 1
Goldsmith, S. R., & Stockerl-Goldstein, K. E. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.01.009 · Cited by 1
The Path Forward in Multiple Myeloma: 2021 Jan Waldenstrom Award Lecture
Rajkumar, S. V. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.04.021 · Cited by 1
Self-citationCADTH (2022) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2022.331 · Cited by 1
Ursule‐Dufait, C., Bengoufa, D., Theodorou, I. D., Villesuzanne, C., & Arnulf, B. (2022) · British Journal of Haematology · doi:10.1111/bjh.18317 · Cited by 1
Goubran, H. A., Sundaram, V., Stakiw, J., & Elemary, M. (2022) · Springer eBooks · doi:10.1007/978-3-031-10131-1_12 · Cited by 1
Guan, A., Shen, K. N., Zhang, L., Cao, X., Su, W., Zhou, D., & Li, J. (2023) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2023.02.009 · Cited by 1
Research Progress on Pathogenesis, Diagnosis and Treatment of Bone Damage in Gaucher Disease
步, 晓. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134802 · Cited by 1
Case 29-2023: A 34-Year-Old Woman with Abdominal Distention and Acute Kidney Injury
Jagannath, S., Anderson, M., Yee, A. J., & Hasserjian, R. P. (2023) · New England Journal of Medicine · doi:10.1056/nejmcpc2027091 · Cited by 1
Positron Emission Tomography/Computed Tomography Transformation of Oncology
Murtazaliev, S., Rowe, S. P., Sheikhbahaei, S., Werner, R. A., & Sólnes, L. B. (2024) · PET Clinics · doi:10.1016/j.cpet.2023.12.010 · Cited by 2
Cardiac Amyloidosis: Approach to Diagnosis
Chopra, N., Arava, S. K., Patel, C. D., Kumar, S., & Seth, S. (2024) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_78_23 · Cited by 1
Self-citationTesta, U., Leone, G. G. M., Pelosi, E., Castelli, G., & Stefano, V. D. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.044 · Cited by 1
Greco, R., Mollica, A., Cirino, B., Gentile, M., Martino, E. A., & Teresa, P. (2024) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1884 · Cited by 1
Lozano, E., Mena, M.-P., Garrabou, G., Cardús, O., Díaz, T., Moreno, D. F., Mañé-Pujol, J., Oliver‐Caldés, A., Battram, A. M., Tovar, N., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0117 · Cited by 1
Prevalence and distribution of M-proteins in the oncologic population affected by solid tumor
de Falco, R., Togo, G., Minopoli, A., Cuomo, M., Rea, D., Meola, S., & Cavalcanti, E. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01095-7 · Cited by 1
Clinical significance of FLC tests in patients without other evidence of hematologic disorder
Shpitzer, D., Cohen, Y. C., Perry, C., Melamed, G., Alapi, H., Benaim, A. R., & Avivi, I. M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01471-4 · Cited by 1
Wang, Q., Andress, B. D., Pazdernik, V., Larson, D. R., Coker, J., Dasari, S., Rajkumar, S. V., Dispenzieri, A. A., Murray, D. L., & Willrich, M. A. V. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae124 · Cited by 1
Self-citationIndolent clonal lymphoid disorders
Delabie, J., & Sakhdari, A. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105715 · Cited by 1
Zhu, X., Feng, Z., Peng, X., Di, T., Li, Y., Bai, J. Y., Ma, T., Li, L., & Zhang, L. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114454 · Cited by 1
Il ruolo della N-glicosilazione nelle catene leggere immunoglobuliniche nell'amiloidosi AL
Russo, M., Nevone, A., VALCOZZENA, I., Lattarulo, F., Mazzini, G., Caminito, S., Rognoni, P., Milani, P., Merlini, G., Palladini, G. O., et al. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00051-2 · Cited by 1
Sun, F., Cheng, Y., Ma, C., Xu, H., Bailey, C., Mery, D. E., Ashby, C., Alapat, D. V., Li, Y., Young, K. H., et al. (2025) · Cancer Biomarkers · doi:10.1177/18758592251344936 · Cited by 1
Liu, Y., Desai, P. M., Nadeem, O., Woyach, J. A., & Alsouqi, A. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473650 · Cited by 1
Uncommon IgA lymphoplasmacytic lymphoma: Case report
Pereira, A. D., Colombo, E. S., Sandes, A. F., Arrais‐Rodrigues, C., & Gonçalves, M. V. (2018) · Clinical Research and Trials · doi:10.15761/crt.1000251 · Cited by 1
Adachi, Y., Takimoto, T., Takeda, M., Matsumoto, K., Takeuchi, N., Kagawa, T., Sakamoto, T., Kasai, T., Sugimoto, C., Inoue, Y., et al. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101313 · Cited by 1
Yassin, A. K., Khsohnaw, N. S. H., Jalal, S. D., Mohammed, A. M., Hasan, K. M., Abdulla, D. A., Badi, A., Safar, B. M., Abdulla, B. K., Shamoon, R. P., et al. (2022) · Advanced medical journal · doi:10.56056/amj.2022.147
Robert A. Kyle, MD: Lessons From a Legend
Rajkumar, S. V. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.030 · Cited by 1
Self-citationTowards a better understanding of monoclonal gammopathy of renal significance
Bianchi, G., & Richardson, P. G. G. (2019) · British Journal of Haematology · doi:10.1111/bjh.15989 · Cited by 1
Myélome multiple : introduction
Michaux, J. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30257-2 · Cited by 1
Singh, G., Savage, N. M., Jillella, A. P., & Bollag, R. J. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3756812 · Cited by 1
Global patterns and trends in multiple myeloma incidence: Age, period and birth cohort analysisPreprint
Li, C., Lin, X. J., Fan, Z., Li, J., Kang, W., Liu, Y., Song, F., & Song, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1977463/v1 · Cited by 1
Genomic Profiling to Contextualize the Results of Intervention for High-Risk Smoldering MyelomaPreprint
Kazandjian, D. G., Diamond, B. T., Papadimitriou, M., Hill, E., Sklavenitis‐Pistofidis, R., Ziccheddu, B., Blaney, P., Chojnacka, M., Durante, M. A., Maclachlan, K. H., et al. (2023) · medRxiv · doi:10.1101/2023.08.30.23294483 · Cited by 1
Impact of Clonal Hematopoiesis on the Carcinogenic Process of Multiple MyelomaPreprint
Koh, Y., Park, C., Cho, G., Ryu, G., Park, J.-M., Yoon, H., Oh, Y. M., Lee, C., An, H., Sun, C.-H., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4672454/v1 · Cited by 1
Strategy for Detecting and Following Monoclonal Gammopathies
Keren, D. F., & Schroeder, L. F. (2024) · doi:10.1002/9781683674023.ch8 · Cited by 1
Light Chain Disorders Associated with COVID-19 VaccinesPreprint
Chandler, R. W. (2025) · Preprints.org · doi:10.20944/preprints202506.0904.v3 · Cited by 1
A Cure, a Cure, My Kingdom for a Cure…
Lonial, S., & Kumar, S. K. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01258 · Cited by 1
Self-citationMonoklonale IgM-Gammopathie besonders riskant
Müller, T. H. (2018) · Im Focus Onkologie · doi:10.1007/s15015-018-3916-z
Wie steht es um Lebenserwartung und Progressionsrisiko bei der MGUS?
Kleeberg, U. R. (2018) · Info Onkologie · doi:10.1007/s15004-018-6042-3
Early Intervention in Multiple Myeloma—Exploring New Frontiers
Kumar, S. K. (2018) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2018.14.1.12
Self-citationMultiples Myelom – Update 2018
Kortüm, K. M., & Einsele, H. (2018) · TumorDiagnostik & Therapie · doi:10.1055/a-0583-8857
The difficult business of assessing new therapies for smouldering multiple myeloma
Zonder, J. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15385
Multiple Myeloma and Primary Sjogren’s Syndrome Combined with Unexplained Elevation of CA-125 Levels
Du, J., Deng, S., Qiu, L., & An, G. (2019) · Journal of Cancer Biology and Therapeutics · doi:10.18314/gjct.v5i1.1465
Touzeau, C., & Moreau, P. (2019) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(19)42057-7
Gammapatía monoclonal de significado incierto: diagnóstico y seguimiento
Pérez, R. R. D. A. (2019) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2019.03.006
What Does a Clinician Need from New Imaging Procedures?
Zamagni, E. (2019) · Springer eBooks · doi:10.1007/978-3-030-19019-4_2
Verebi, C., Talbot, A., Gendron, N., & Hurtado-Nédelec, M. (2019) · Annales de biologie clinique · doi:10.1684/abc.2019.1452
Shin, W. Y., Bang, H. I., Kim, J., Park, R., Shin, J. W., & Choi, T. Y. (2019) · Laboratory Medicine Online · doi:10.3343/lmo.2019.9.4.263
Monoclonal gammopathy associated neuropathy: Focusing on IgM M-protein associated neuropathy
Pruppers, M. H. J., Merkies, I. S. J., & Notermans, N. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814572-2.00005-4
Hirji, S. H., Maeng, M. M., Tooley, A. A., Soderquist, C. R., Annunziata, J., & Kazim, M. (2020) · Orbit · doi:10.1080/01676830.2020.1760312
MDS Mimics Including CHIP, ICUS, and CCUS
Bejar, R. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_6
Braun, W. E., Herlitz, L., Li, J., Schold, J. D., Poggio, E. D., Stephany, B. R., Fatica, R. A., Nally, J. V., Brown, K., Fairchild, R. L., et al. (2020) · Clinical Transplantation · doi:10.1111/ctr.14131
Multipl Myelom Tanılı Hastaların Sitogenetik Özellikleri ve Prognoza Etkisi
Kars, T. U., Tekinalp, A., Dikici, H. Z., Demi̇rci̇oğlu, S., & Çeneli̇, Ö. (2020) · LLM Dergi · doi:10.5578/llm.20219902
Novel investigations and treatment outcomes in systemic AL amyloidosis
Manwani, R. (2021) · UCL Discovery (University College London)
Genomic Landscape and Clonal Evolution of AML
Noerenberg, D., Damm, F., & Bullinger, L. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_5
Rosso, C., Giscombe, L., Tannous, T., & Keating, M. (2021) · SAGE Open Medical Case Reports · doi:10.1177/2050313x211019784
Role of the bone marrow microenvironment in tumor transformation of plasma cell dyscrasias
Козич, Ж. М., Смирнова, Л. А., & Мартинков, В. Н. (2021) · Health and Ecology Issues · doi:10.51523/2708-6011.2021-18-1-2
Hammad, Z. A. A., Hernández, E., & Tate, S. (2021) · Journal of Family Medicine · doi:10.26420/jfammed.2021.1261
Clinical study of multiple myeloma and treatment responses in a tertiary care centre
Giridhar, I. S. M., Yadlapalli, C. D., Gullipalli, M., Mushini, V., Sarma, Y. S., & Chakradhar, M. (2021) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20214417
Козич, Ж. М., Смирнова, Л. А., & Мартинков, В. Н. (2020) · Health and Ecology Issues · doi:10.51523/2708-6011.2020-17-1-17
El‐Khoury, H., Lee, D. J., Alberge, J.-B., Redd, R. A., Cea-Curry, C. J., Perry, J. F., Barr, H., Murphy, C., Sakrikar, D. S., Barnidge, D. R., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3978571
MBBS, F. B. J. B., Clark, M. D. M., & DM, B. S. W. (2019) · doi:10.1002/9781119398929.ch7
Multiple Myeloma: From Scintigraphy to PET/CT and Importance of Functional Imaging
Görür, G. D., & Hekimsoy, T. (2022) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2022.0011
Metadata
- Authors
- Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-18
- Volume
- 378
- Issue
- 3
- Pages
- 241-249
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5852672
- OpenAlex
- W2785817645
- Cited by
- 647
- References
- 30
- Citations by year
- 2026: 62 · 2025: 90 · 2024: 101 · 2023: 81 · 2022: 75 · 2021: 76 · 2020: 80 · 2019: 47 · 2018: 33
- FWCI
- 42.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA107476, CA168762, CA186781)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, plasma cell dyscrasia, free light chain ratio, risk factors, survival, long-term follow-up
- MeSH terms
- Adult, Aged, Bone Marrow Examination, Female, Follow-Up Studies, Glycoproteins, Humans, Immunoglobulin M, Immunoglobulin Light Chains, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prognosis, Risk Factors, Proportional Hazards Models, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
